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ABSTRACT 
Background 
The Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) has been 
shown to be a reliable and valid questionnaire measuring health-related quality of life 
(HRQoL) in the US sickle cell disease (SCD) population. The study objective was to test the 
validity and reliability of the ASCQ-Me for use in the UK.  
Methods 
The US ASCQ-Me, Hospital Anxiety and Depression Scale (HADS), self-reported symptoms, 
and Medical Outcome Survey Short Form 36 (SF-36) were administered to 173 patients with 
SCD. Clinical severity was assessed by the number of painful episodes indicated by hospital 
admissions.  
Results 
The results showed that the item banks of the UK ASCQ-Me had good internal consistency. 
Anxiety and depression were strongly correlated with the emotional, and social item banks 
of the UK ASCQ-Me, with moderate correlations between the UK ASCQ-Me item banks and 
SF-36 components suggesting convergent validity. A confirmatory factor analysis confirmed 
the conceptual framework of the scale as being the same as the US ASCQ-Me, indicating 
construct validity. Known groups validity was found, with the ASCQ-Me being able to 
differentiate by SCD severity groups.  
Conclusion 
The analysis of the sample shows evidence of both validity and reliability of the ACCQ-Me 
for use in the UK SCD population.  
KEY WORDS 
• Sickle Cell Disease; Quality of Life; ASCQ-Me; SF-36; Validity  
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BACKGROUND 
Sickle cell disease (SCD) is an inherited structural haemoglobin disorder, common in people 
whose family origins were from Africa, but also seen in people with family origins in the 
Eastern Mediterranean, Middle East and South Asia. In England, it is now the most common 
serious inherited disorder, with a birth prevalence of approximately 1 in 2000 [1]. There are 
three primary genotypes of SCD: haemoglobin SS (HbSS); haemoglobin SC (HbSC); and 
haemoglobin Sβ-thalassemia Hb (SβThal). An estimated 12,500 to 15,000 people in the UK 
have SCD [2]. 
SCD is one of the most common reasons for hospital admission and has the highest rate of 
multiple admissions for individual patients in the UK [3]. SCD has been found to adversely 
affect health-related quality of life (HRQoL), but there are few studies that have evaluated 
SCD HRQoL in adults in Europe. In a sample of 96 adults with SCD one study [4] found that 
HRQoL was significantly lower than that of the UK general population.  To date, HRQoL has 
however, been assessed in adults with SCD using generic measures [5, 6], such as the RAND 
Medical Outcomes Study 36-item Short Form Survey (SF-36) [7] or EuroQol five-dimensional 
questionnaire (EQ-5D) [8]. Generic measures are required to enable comparison with other 
diseases as well as with the general population [9]. These measures, however, do have 
limitations as they do not measure the specific effects of the disease, and thus may not 
detect subtle, but clinically important variations in quality of life [10]. Disease-specific 
measures are likely to be more sensitive than generic measures to clinically significant 
change [11] as well as being more relevant to the disease under study [9].  
HRQoL is an important outcome of clinical trials in SCD (Pecker et al, 2017), however there is 
currently no disease-specific HRQoL measure for adults with SCD that has been validated for 
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use in the UK [6]. Two disease-specific HRQoL measures have been developed and validated 
in the US: the Sickle Cell Impact Measurement Scale (SIMS) [12], and the Adult Sickle Cell 
Quality of Life Measurement Information System (ASCQ-Me) [13, 14]. The SIMS was adapted 
from four existing questionnaires: the Arthritis Impact Measurement Scale (AIMS) [15] and 
three generic measures. It has four domains: pain; physical functioning; emotional well-
being; social functioning. The SIMS validation study compared HRQoL in adults with SCD and 
rheumatoid arthritis (RA). No difference was found between the two patient groups on 
overall HRQoL but people with SCD scored higher than those with RA on physical and social 
domains [12]. The ASCQ-Me items were derived from research with adults who have SCD 
and their health care providers. It has been validated showing the item banks to be sensitive 
to SCD severity based on a self-reported medical history checklist, and validity has been 
shown utilising item response theory [16, 17]. It has was found that the ASCQ-Me also had 
similar disciminant validity to the Patient-Reported Outcomes Measurement Information 
System (PROMIS)[18] in regards to SCD severity [17]. Physical function, pain, and the ability 
to engage in social roles and activities, as measured by the ASCQ-Me, were most affected by 
SCD severity. All ASCQ-Me validation studies to date have been conducted in US samples. It 
is necessary to validate patient reported scales for use in their country, as definitions of 
quality of life are affected by national culture patterns [19, 20]. 
The study objective was to test the validity and reliability of the ASCQ-Me [13, 14] for use in 
the UK. This measure was chosen in preference to the SIMS, which consists of 142 items and 
was therefore considered too long to be practical by both clinicians and patients [12]. 
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METHODS 
Study Design 
This was a cross-sectional study conducted at four National Health Service (NHS) hospitals in 
London.  
Population 
Patients were invited to take part if they were adults aged ≥18 years, had a diagnosis of 
Sickle Cell Anaemia HbSS, Sickle C Disease HbSC or Sickle Beta Thalassæmia (Hb SβThal) and 
their haematologist considered them well enough to answer the ASCQ-Me (either assisted 
or unassisted)[21].  
Data Collection 
Eligible patients were advised about the study by their haematologist when they attended a 
routine outpatient clinic appointment or, hospital day care unit . Once consented, 
participants were given a copy of the questionnaire which they could complete in clinic or 
take home and return in a postage-paid envelope.  
Measures 
The questionnaire pack included: 
• ASCQ-Me version 2.0 Short Form [14]. A 30-item measure with 7 item banks: Pain 
episode frequency (2 items); Pain episode severity (3 items); Pain impact (5 items); 
Emotional impact (5 items); Social impact (5 items); Stiffness (5 items); and Sleep 
impact (5 items). The latter five item banks are each scored from 5 (never) to 1 
(always). Scores on each subscale are standardised to have a mean of 50 and a 
standard deviation of 10. A higher score represents better HRQoL on all item banks, 
apart from pain episode frequency and severity, on which higher scores indicate 
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greater frequency/severity. In the US, the ASCQ-Me has been shown to have 
excellent internal consistency for each item bank (≥.90) and the item banks differed 
significantly between SCD severity levels [16].   
• The Medical Outcomes Study Short Form 36 (SF-36) [7] to assess generic HRQoL. The 
SF-36 is a 36-item measure with eight subscales: physical function; role limitation 
caused by physical function; pain; general health; energy/vitality; social function; 
role limitation caused by emotional difficulties; mental health. It also provides two 
composite scores for physical (PCS) and mental (MCS) HRQoL. Scores are 
transformed to a 0-100 scale on which the population mean is 50 and the standard 
deviation is 10. A higher score signifies better HRQoL. The SF-36 has previously 
shown to have good reliability and validity in the SCD population [22].  
• Anxiety and depression were assessed with the Hospital Anxiety and Depression 
Scale (HADS) [23]. The HADS is a 14-item measure with individual scales for anxiety 
and depression. Each scale is scored from 0 – 21 with a higher score signifying 
greater anxiety or depression. A score of ≥8 indicates possible clinical 
depression/anxiety and a score of ≥11 indicates probable clinical depression/anxiety. 
The HADS has previously been validated in a clinical population [24], and been 
utilised in the UK SCD population [25].  
• Symptoms:  current pain, stiffness and fatigue were assessed with 10-point Visual 
Numeric Scales (VNS). Scores ranged from 0 to 10, with the higher scores indicating 
more pain, stiffness or fatigue [26].  
• Number of days of college/work missed over the past month due to SCD, if 
applicable 
• Current exercise tolerance: good, moderately reduced or severely reduced 
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• Number of painful crises managed at home during an average month/three month 
period over past two years 
Routinely collected clinical data were extracted from participants’ medical notes with their 
informed consent. This included: 
• Genotype (HbSS, HbSC or Hb SβThal)  
• Number of hospital admissions with pain crisis during past two years 
• Acute chest syndrome: Number requiring transfusion over past 2 years 
• History of: 
o Avascular necrosis (AVN) of hip  
o Stroke or recurrent transient ischemic attack (TIA) 
o Priapism 
o Severe, renal impairment: Requiring renal replacement treatment 
o History of Retinopathy with visual impairment 
o Elevated tricuspid regurgitation (TR) jet velocity  
o Catheter diagnosis of pulmonary hypertension 
o Recurrent ankle ulceration during past 2 years 
o Chronic pain: Persistent pain most days lasting more than 6 months 
• Current medication with regular transfusion, medication with hydroxycarbamide, 
number of days of oral opioids used per week 
Disease severity was classified based on the following criteria:  
• People who have had ≥3 hospital admissions on average in the past 12 months vs 
those who have had <3 admissions on average.  
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These disease severity criteria are the standard for pain episodes and have previously been 
used as entry criteria for a trial of hydroxyurea (Charache, 1995). 
 
Analysis 
Study data were analysed using IBM SPSS Statistics 23®. The significance level was set at 
p<0.01 in order to minimise the risk of a type I error. The pattern of missing data was 
evaluated using the missing data function. Any participant with more than 50% missing data 
was removed from the analysis. Little’s Missing Completely At Random (MCAR) test was 
conducted to check if there were any systematic differences between the missing values 
and the observed values [27]. All analyses were carried out as instructed by a 
predetermined statistical analysis plan that detailed all planned analyses prior to data 
collection.  
Reliability. Internal consistency was measured using Cronbach’s alpha coefficient to test the 
degree to which items in each ASCQ-Me subscale were related to each other. There are no 
tests of statistical significance for these estimations, though alphas >0.70 are generally 
considered acceptable for aggregate data, with ≥0.80 to <0.90 indicating good consistency, 
and >0.90 excellent consistency [28]. 
Validity. Content validity, defined as the extent to which the instrument measures the 
concept of interest, was confirmed prior to data collection by obtaining the views of 
patients with SCD and experts working in SCD on the questionnaire items to ensure that 
they capture the different components of SCD HRQoL. Construct validity, defined as 
evidence that the relationship among items conform to a priori hypotheses, was tested by 
examining convergent and known groups validity [29]. Convergent validity assesses 
measures that have an expected logical relationship with each other. This was tested by 
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comparing the ASCQ-Me with the SF-36, HADS, and self-reported symptoms using Pearson’s 
correlation coefficient. Known groups validity assesses the extent to which measures are 
able to distinguish differences and similarities between sub samples, this was tested by 
comparing groups expected to differ on ASCQ-Me subscales using an Independent sample t-
tests or analysis of variance (ANOVA). Confirmatory factor analysis (CFA) of the ASCQ-Me 
was performed to examine the validity of the 5-factor structure. Further details of the 
analysis are included in the online supplementary material. 
For correlation of convergent validity Pearson’s R values of <0.20 are considered a very 
weak correlation, ≥0.20 to <0.40 a weak correlation, ≥0.40 to <0.60 moderate, ≥0.60 to 
<0.80 strong, and >0.80 a very strong correlation [30]. 
Known groups validity was tested using independent sample t-tests or analysis of variance 
(ANOVA) tests that were used to compare the means between groups. Scores were 
compared between: 
• People with different types of SCD - HbSS, HbSC, and Hb SβThal.  
• People who have an average of ≥3 hospital admissions per year over the past 2 years 
vs <3 hospital admissions 
The fit of the CFA model was assessed with comparative fit index (CFI), and root mean 
square error of approximation (RMSEA). CFI greater than 0.90 was considered an acceptable 
fit, and RMSEA <0.07. RMSEA and CFI are standard statistical tests in CFA that assess the 
goodness of fit, this assesses how well the model-implied relationships of the items and the 
item banks are equivalent to the relationships in the sample data [31]. CFA was run using 
IBM® SPSS Statistics 23® AMOS 25.0. The standardized regression weights outputted in the 
CFA (Table 4) allow us to compare the means of individual items to the mean of each item 
bank in order to assess accuracy of fit of each item bank.  
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RESULTS 
Socio-Demographic & Clinical Details 
A total of 224 patients consented to the study, of which 173 (77.2%) completed and 
returned the questionnaire. Sociodemographic details of the sample analysed are shown in 
Table 1. The sample had an average age of 36 years (range 18-78 years), were mostly 
women (57.8%) and the vast majority indicated that they were either black or black British 
(93.0%).  
The clinical characteristics of the sample are reported in Table 2. Patients were mostly HbSS 
(72.3%), 20.8% with a HbSC diagnosis and a smaller number Hb SβThal (4.0%). The number 
of transfusions used to treat acute chest syndrome over the previous 2 years was 0.7 (2.3). 
The results showed that the majority of participants had at least one pain crises per month 
on average (72.8%). 
Scores on the SF-36 indicated impaired HRQoL; the physical composite score was more than 
one standard deviation (SD) below the standardised norm and the mental composite score 
was half a SD below. In reviewing the ASCQ-Me standardised scores for each item bank, the 
worst quality of life scores were seen in the social functioning item bank with a mean (SD) of 
14.43 (5.22), followed by sleep 15.49 (4.67). Although HADS mean scores were in the 
normal range, HADS scores show that 46% of participants scored above the level for 
possible clinical anxiety and 41% for possible depression (Table 3). For 88% of the sample, 
their last pain attack had interfered with some aspect of their life and for 47% had lasted for 
4 days or more.  
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Reliability 
Cronbach’s alpha for the five primary ASCQ-Me item banks indicated that the sleep impact 
item bank had acceptable consistency (0.78), with the remaining 4 item banks showing 
excellent consistency (0.92-0.96).  
Construct Validity 
The CFA (Table 4) was assessed with the model fit indices comparative fit index (CFI), and 
root mean square error of approximation (RMSEA). All but one of the items loaded to their 
item respective bank (shown by a standardised regression weight of >0.40). The CFI met the 
minimum criteria for acceptable fit at 0.94, the RMSEA marginally exceeded the threshold of 
<0.07 at 0.08. The item “How often was it very easy for you to fall asleep?” did not load to 
the Sleep factor (<0.40), therefore it was removed from the model. 
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Convergent Validity 
All correlations between ASCQ-Me item banks and the SF-36 and HADS were shown to be 
statistically significant (p<0.001). For the HADS (Table 5), as expected, there was a strong 
relationship between the HADS anxiety and depression scales, and the emotional (Anxiety: 
r=-0.66, Depression: r=-0.64), and social impact ASCQ-Me banks (Anxiety: r=-0.55, 
Depression: r=-0.58). In reviewing the correlation between the ASCQ-Me item banks and SF-
36 components, overall there were a number of moderate relationships. There was a 
stronger relationship between the ASCQ-Me pain item bank and the SF-36 physical 
component score (PCS, r=0.52), than with the pain item bank and the SF-36 mental 
component score (MCS, r=0.37). The emotional impact and social impact item banks of the 
ASCQ-Me had the strongest correlations with the mental component score of the SF-36 
(Emotional: r=-0.68, Social: r=-0.61). 
Known Groups Validity 
There were no significant differences (p>0.01) between patients with HbSS, HbSC, or Hb 
SßThal on any of the items banks (Table 6). Independent sample T-tests showed that all five 
of the ASCQ-Me item banks were able to significantly discriminate between a group of SCD 
patients that were admitted to the hospital three times or more on average in the previous 
12 months compared to those that had been admitted twice or less (p<0.01).  
In exploratory analysis of the previous medical history of the SCD patients it was found that 
there were significant differences on all of the ASCQ-Me item banks between patients who 
had a history of persistent pain most days lasting more than 6 months and those who did 
not (p<0.001) (Table S1). Furthermore, when reviewing medical history of avascular necrosis 
of hip (AVN), there were significant results for the stiffness ASCQ-Me item bank (p<0.01), 
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with patient that have had a history of AVN having lower scores indicating that they 
experience greater stiffness impact. There were no other significant results for any of the 
medical history items.  
DISCUSSION 
The results and analyses in this study show strong evidence of validity and reliability for the 
ASCQ-Me to be used as a measure of disease-specific HRQoL in adults with SCD in the UK. 
All of the item banks had good internal consistency, with the majority being excellent, after 
removal of one sleep item. The CFA indicated that the conceptual framework of the item 
banks fitted well for each item, and with the US ASCQ-Me [16]. The RMSEA test of model fit 
did not meet the minimum threshold for acceptance, however these values were shown to 
be akin to other self-reported questionnaires with a similar number of items [32], and 
similar to that seen in Keller et al [16].  
In reviewing the validity of the ASCQ-Me, the scale was compared with a generic QoL 
measure the SF-36, and the HADS. All ASCQ-Me item banks correlated significantly with the 
SF-36 subscales. As would be expected, the emotional impact item bank of the ASCQ-Me 
correlated more strongly with the SF-36 mental composite score than with the physical 
composite score, whereas the pain, stiffness and pain crisis frequency item banks correlated 
more strongly with the physical than the mental composite score. Sleep impact, social 
impact and pain crisis severity also correlated more strongly with the SF-36 physical than 
mental composite score, but only marginally. Anxiety and depression were strongly 
correlated with the emotional and social item banks of the ACSQ-Me, but weaker with the 
pain, sleep, and stiffness items. Although there is only a weak relationship between some 
item banks and the HADS, the stronger relationship between the HADS and the emotional 
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ACSQ-Me item bank is to be expected, due to the HADS probing patients on the emotions 
surrounding depression and anxiety. We can therefore argue that the ASCQ-Me has 
convergent validity.    
In reviewing the known-groups validity data, the ASCQ-Me did not distinguish between SCD 
diagnoses, supporting previous work using generic HRQoL measures [22, 33, 34]. This does 
however, contrast with the systematic review of HRQoL in SCD by Panepinto and Bonner [6] 
that did report a difference between genotypes, however they did not provide specific 
details on the differences or of which study/ies reported this finding, making any further 
interpretation difficult. It should be noted however, that there were only seven participants 
of the sample with SβThal, indicating less reliability of the diagnoses known groups validity 
test. However, it is not uncommon for clinical indicators to not predict HRQoL; the 
relationship between disease severity in long-term conditions and HRQoL is not always a 
linear one [35]. Keller [17] stated that SCD genotypes, due to the broad variation of 
symptomatology, are an unreliable indicator of disease severity. However, previous 
literature has suggested HBSS have more severe symptoms [36-38]. The current study found 
that HBSS had the poorest HRQoL on the ASCQ-Me item banks in comparison to the other 
genotypes, although this was not statistically significant.  
The ASCQ-Me was able to successfully distinguish between groups of patients that were 
frequently admitted to hospital compared to those that were not. As would be expected, 
the results showed that patients who were admitted to hospital more had poorer quality of 
life in all ASCQ-Me items banks. Poorer scores on the SF-36 physical component summary 
were associated with a greater number of visits to the emergency department in one study 
[39] but another found no relationship between SF-36 scores and hospital service use or 
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general practitioner visits [4]. The reason for these inconsistencies is most likely due to a 
number of factors, including clinical and socio-demographic differences between the 
samples, and a lack of reliable, valid, and consistent measurements of healthcare utilisation.   
When compared to the ASCQ-Me field-test participants in Keller et al [16], our sample 
reported more pain crises during the past 12 months, but the duration of participants’ most 
recent crisis, the percentage reporting that their last pain crisis interfered with their life and 
the level of pain severity experienced during the last pain crisis were very similar in the two 
samples. The current study also found that HRQoL in adults with SCD was impaired in 
relation to the general population, which confirms the findings of other research in this 
area.  Anie, Steptoe, et al [4] used the SF-36 and found that HRQoL was significantly lower 
than that of the UK general population. Pain, and the use of affective coping strategies, 
defined as catastrophizing, anger and fearful self-statements, praying and hoping, and 
isolation, were associated with poorer HRQoL. The ASCQ-Me provides further insight into 
HRQoL specific to SCD that generic measures such as the SF-36 fail to measure. It was seen 
that sleep impact and stiffness were of importance to quality of life as they both correlated 
with the SF-36 PCS and MCS, and the HADS anxiety and depression scales. This shows the 
importance of using a disease-specific measure such as the ASCQ-Me to assess HRQoL in 
SCD patients.  
Using the ASCQ-Me in clinical practice could provide useful information to healthcare 
providers. The tool is easy for patients to complete and for clinicians to interpret. It could be 
used to obtain reliable assessments at each clinic visit of several important issues for people 
with SCD including  stiffness, sleep, pain, emotional, and social impact of SCD. Not all of 
these factors are routinely assessed however this study has shown that they are negatively 
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associated with the physical and mental well-being and therefore merit further attention in 
the clinical setting. 
This study had a number of limitations. It could be argued that the SCD population was not 
representative of the UK general population as recruitment was only in London. This is also 
a limitation of other research that has examined HRQoL in people with SCD in the UK [4]. 
However, approximately two-thirds of people with SCD in the UK live in London with most 
others living in other large urban areas [41]. Although the analysis shows relationships 
between the measured variables, due to the limitations of correlation analysis, cause cannot 
be inferred. As some data were extracted from patients’ medical notes, we acknowledge 
that there may be some inconsistencies in these data;  this is an issue for all studies that 
extract data from medical notes.  
Future studies could be carried out to provide further reliability and validity for the ASCQ-
Me scale, this includes test-retest reliability. By measuring changes in severity mapped 
against changes in ASCQ-Me scores over time any clinical responsiveness of the scale would 
show further validity of the questionnaire. Such reliabiltiy and validity tests have so far not 
been carried out on the ASCQ-Me US version.  
CONCLUSION 
 The analyses show strong evidence of reliability and validity for the ASCQ-Me  to be used as 
a measure of disease-specific HRQoL in SCD in the UK, replicating some of the findings of the 
US ACSQ-Me. The UK measure will be a valuable tool for assessing the HRQoL of adults with 
SCD, providing a useful outcome measure in both research and clinical practice.  
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TABLES 
Table 1. Patient Socio-Demographic Characteristics (n=173) 
Variable  
Age years, mean (SD) 36.1 (12.5) 
Gender, n (%)  
Female 100 (57.8) 
Male 69 (39.9) 
Undisclosed 4 (2.3) 
Ethnicity, n (%)  
Black or Black British – African 118 (68.2) 
Black or Black British – Caribbean 39 (22.5) 
Black or Black British – Other 4 (2.3) 
White and Black African 3 (1.7) 
Other Mixed  1 (0.6) 
White British 1 (0.6) 
Undisclosed 7 (4.0) 
Employment, n (%)  
Full time work 64 (37.0) 
Unemployed 42 (24.3) 
Part time work 24 (13.9) 
Other 16 (9.2) 
Student 15 (8.7) 
Full time homemaker 6 (3.5) 
Undisclosed 6 (3.5) 
Highest Educational Qualification, n (%)  
Degree / Equivalent 70 (40.5) 
A Level / Equivalent 36 (20.8) 
Post graduate  34 (19.7) 
GSCE / O level / Equivalent 25 (14.5) 
No formal qualifications 4 (2.3) 
Undisclosed 4 (2.3) 
 
 
 Table 2. Clinical Characteristics (n=173) 
Variable  
SCD Diagnosis, n (%)  
HbSS 125 (72.3) 
HbSC 36 (20.8) 
Hb SβThal 7 (4.0) 
Missing 5 (2.9) 
Medical History, n (%)  
Avascular necrosis (AVN) of hip 39 (22.5) 
Stroke or recurrent TIA 19 (11.0) 
Priapism† 19 (26.0) 
Severe, renal impairment: Requiring renal replacement treatment 11 (6.4) 
History of Retinopathy with visual impairment 37 (21.4) 
Elevated tricuspid regurgitation (TR) jet velocity 10 (5.8) 
Catheter diagnosis of pulmonary hypertension 5 (2.9) 
Recurrent ankle ulceration during past 2 years 14 (8.1) 
Chronic Pain: Persistent pain on most days lasting more than 6 months 52 (30.1) 
Acute Chest Syndrome – Transfusion required during the past 2 years, 
mean (SD)  0.7 (2.3) 
Pain Crises, n (%)  
Had 3 or more hospital admissions with pain crises in the previous 12 
months 
13 (7.5) 
Had 1 or more pain crises per month on average 126 (72.8) 
Take 2 or more doses of opiate analgesia per week on average 92 (53.2) 
† Percentage frequency calculated with male sample only 
Table 3. Patient Reported Descriptive Data 
Variable  
Current Pain VNS, mean (SD) 2.8 (2.9) 
Current Stiffness VNS, mean (SD) 2.5 (2.8) 
Current Fatigue VNS, mean (SD) 4.0 (3.0) 
HADS Anxiety, mean (SD) 7.6 (4.4) 
HADS Anxiety Classifications, n (%)  
Non-cases (score of 0 to 7) 90 (54%) 
Possible cases (score of 8 to 10) 35 (21%) 
Probable cases (score of 11 to 21) 43 (25%) 
HADS Depression, mean (SD) 7.1 (4.06) 
HADS Depression Classifications, n (%)  
Non-cases (score of 0 to 7) 97 (59%) 
Possible cases (score of 8 to 10) 46 (28%) 
Probable cases (score of 11 to 21) 21 (13%) 
SF-36 Physical Component Summary, mean (SD)* 37.26 (10.93) 
SF-36 Mental Component Summary, mean (SD)* 44.02 (12.16) 
ASCQ-Me: In the past 12 months, how many sickle cell pain attacks 
(crises) did you have? n (%)  
I did not have a pain attack 20 (11.6) 
0 11 (6.4) 
1 20 (11.6) 
2 22 (12.7) 
3 21 (12.1) 
4 or more 79 (45.7) 
ASCQ-Me: When was your last pain attack?, n (%)  
I’ve never had a pain episode  6 (3.5) 
I have one right now 6 (3.5) 
Less than a week ago 22 (12.7) 
1-4 weeks ago 9 (5.2) 
1-6 months ago 33 (19.1) 
7-11 months ago 45 (26.0) 
1-5 years ago 26 (15.0) 
More than 5 years ago 26 (15.0) 
Variable  
ASCQ-Me Patient rating of pain severity in last attack (0 to 10), mean 
(SD) 
7.17 (0.17) 
ASCQ-Me: How much did your last pain attack (crisis) interfere with your 
life? n (%)  
I’ve never had a pain attack (crisis)  3 (2) 
Not at all, I did everything I usually do  17 (10) 
I had to cut down on some things I usually do  44 (25) 
I could not do most things I usually do  41 (24) 
I could not take care of myself and needed some help from family or 
friends  40 (23) 
I could not take care of myself and needed constant care from family, 
friends, doctors, or nurses 28 (16) 
ASCQ-Me: About how long did your most recent pain attack (crisis) last?  
I’ve never had a pain attack (crisis) 4 (2) 
Less than 1 hour  8 (5) 
1-12 hours  25 (15) 
13-23 hours  7 (4) 
1-3 days  47 (27) 
4-6 days  38 (22) 
1-2 weeks  28 (16) 
More than 2 weeks 16 (9) 
ASCQ-Me Pain Item Bank (7 day recall), mean (SD)   
How often did you have pain so bad that you could not do anything for a 
whole day? 3.27 (1.18) 
How often did you have pain so bad that you could not get out of bed? 3.49 (1.20) 
How often did you have very severe pain?  3.32 (1.17) 
How often did you have pain so bad that you had to stop what you were 
doing? 3.18 (1.19) 
How often did you have pain so bad that it was hard to finish what you 
were doing? 3.21 (1.18) 
ASCQ-Me Sleep Item Bank (7 day recall), mean (SD)  
How often did you stay up most of the night because you could not fall 
asleep? 3.00 (1.89) 
How often was it very easy for you to fall asleep?*  2.79 (1.13) 
How often did you have a lot of trouble falling asleep? 3.06 (1.21) 
Variable  
How often did you stay up all night because you could not fall asleep? 3.39 (1.17) 
How often did you stay up half the night because you could not fall asleep? 3.16 (1.11) 
ASCQ-Me Stiffness Item Bank (7 day recall), mean (SD)  
How often were your joints very stiff when you woke up? 3.11 (1.29) 
How often were your joints very stiff during the day? 3.29 (1.21) 
How often were your joints so stiff during the day that you could not 
move? 3.88 (1.03) 
How often did you wake up so stiff that you could not move? 3.89 (1.17) 
How often did it take you a very long time to get out of bed because of 
stiffness? 3.69 (1.20) 
ASCQ-Me Emotional Distress Item Bank (7 day recall), mean (SD)  
How often did you feel completely hopeless because of your health? 3.27 (1.39) 
How lonely did you feel because of your health problems? 3.31 (1.38) 
How depressed were you about your health problems? 3.40 (1.40) 
How much do you worry about getting sick? 2.71 (1.39) 
How often were you very worried about needing to go to the hospital? 3.04 (1.42) 
ASCQ-Me Social Functioning Item Bank (30 day recall), mean (SD)  
How much did you rely on others to take care of you because of your 
health? 3.24 (1.17) 
How often did your health slow you down? 2.65 (1.21) 
How often did your health make it hard for you to do things? 2.74 (1.14) 
How often did your health keep you from going out? 2.92 (1.16) 
How much did your health make it hard for you to do things with your 
friends? 2.87 (1.20) 
Standardised Total ASCQ-Me Item Bank, mean (SD) 
 
 
Pain 47.20 (10.05) 
Sleep 50.04 (7.86) 
Stiffness  49.22 (9.67) 
Emotional Distress  46.63 (10.39) 
Social Functioning  46.44 (10.15) 
*Reverse scored 
Table 4. Confirmatory Factor Analysis of the ASCQ-Me 
Item 
Standardised 
Regression 
Weight* 
Pain  
How often did you have pain so bad that you could not do anything 
for a whole day? 
0.91 
How often did you have pain so bad that you could not get out of 
bed? 
0.88 
How often did you have very severe pain? 0.91 
How often did you have pain so bad that you had to stop what you 
were doing? 
0.92 
How often did you have pain so bad that it was hard to finish what 
you were doing? 
0.95 
Sleep  
How often did you stay up most of the night because you could not 
fall asleep? 
0.57 
How often was it very easy for you to fall asleep? <0.40 
How often did you have a lot of trouble falling asleep? 0.87 
How often did you stay up all night because you could not fall 
asleep? 
0.90 
How often did you stay up half the night because you could not fall 
asleep? 
0.94 
Stiffness  
How often were your joints very stiff when you woke up? 0.84 
How often were your joints very stiff during the day? 0.80 
How often were your joints so stiff during the day that you could not 
move? 
0.87 
How often did you wake up so stiff that you could not move? 0.90 
How often did it take you a very long time to get out of bed because 
of stiffness? 
0.90 
Emotional Distress  
How often did you did you feel completely hopeless because of your 
health? 
0.90 
How lonely did you feel because of your health problems? 0.90 
How depressed were you about your health problems? 0.86 
How much do you worry about getting sick? 0.76 
How often were you very worried about needing to go to the 
hospital? 
0.76 
Social Functioning  
Item 
Standardised 
Regression 
Weight* 
How much did you rely on others to take care of you because of 
your health? 
0.76 
How often did your health slow you down? 0.93 
How often did your health make it hard for you to do things? 0.93 
How often did your health keep you from going out? 0.83 
How much did your health make it hard for you to do things with 
your friends? 
0.84 
*The regression weight can be interpreted as the correlation between each item and its respective item bank   
Table 5. ASCQ-Me Convergent Validity: Correlations with SF-36 & HADS 
 
 
Pain Sleep Impact Stiffness 
Emotional 
Impact 
Social 
Impact 
Pain Crisis 
Frequency 
Pain Crisis 
Severity 
SF-36 Physical 
Component Score 
r 
n 
0.52* 
160 
0.51* 
164 
0.51* 
168 
0.48* 
165 
0.65* 
169 
0.58* 
171 
0.39* 
170 
SF-36 Mental 
Component Score 
r 
n 
0.37* 
160 
0.46* 
 164 
0.37* 
 168 
0.68* 
165 
0.61* 
 169 
0.35* 
171 
-0.34* 
170 
HADS Anxiety 
r 
n 
-0.24* 
160 
-0.38* 
163 
-0.35* 
165 
-0.66* 
163 
-0.55* 
167 
-0.31* 
168 
-0.23* 
167 
HADS Depression 
r 
n 
-0.35* 
154 
-0.37* 
158 
-0.34* 
161 
-0.64* 
159 
-0.58* 
162 
-0.35* 
164 
-0.27* 
163 
*Significant result (p<.01)
Table 6. ASCQ-Me Known Groups Validity  
SCD Diagnosis (ANOVA) Hospital Admissions (T-test)   
HbSS HbSC Hb 
SβThal 
F(df), p ≥3 Hospital 
admissions 
in the 
previous 12 
months 
< 3 Hospital 
admissions 
in the 
previous 12 
months 
t(df), p       
Pain 
Impact 
46.62 49.42 49.16  1.16  
(2, 156), 
0.316 
39.42 48.09 2.79 (153), 
0.006* 
      
Stiffness 
Impact 
48.81 50.29 52.67  0.78  
(2, 162), 
0.460 
41.64 50.23 3.17 (161), 
0.002* 
      
Sleep 
Impact 
49.63 51.21 50.57  0.56  
(2, 159), 
0.571 
44.35 50.60 2.79 (159), 
0.006* 
      
Emotional 
Impact 
45.95 50.56 45.58  2.81  
(2, 159), 
0.63 
36.15 47.83  4.12 (159), 
0.000* 
      
Social 
Impact 
45.56 50.52 45.460  3.47  
(2, 164), 
0.34 
39.58 39.58 4.193 (19), 
0.001*  
      
*Significant result (p<.01) 
 
 
Table S1. ASCQ-Me Medical History Differences 
 Medical History - Avascular Necrosis of Hip Medical History - Chronic pain: Persistent Pain 
Most Days Lasting More than 6 months 
Stroke or recurrent transient ischemic attack 
 
No Yes t(df), p No Yes t(df), p No Yes t(df), p 
Pain 
Impact 
48.31 43.94 2.23 (157), 
0.023 
49.78 41.55 5.66 (113), 
<0.001* 
47.56 45.84 0.643 (156), 
0.521 
Stiffness 
Impact 
50.54 45.49 3.33 (9), 
0.001* 
51.85 43.87 5.37 (165), 
<0.001* 
49.74 46.55 1.359 (164), 
0.176 
Sleep 
Impact 
50.64 47.84 1.62 (47), 
0.112 
51.85 45.78 4.82 (161), 
<0.001* 
49.99 50.44 -0.231 (160), 
0.818 
Emotional 
Impact 
47.52 44.60 1.54 (162), 
0.125 
49.15 41.75 4.53 (162), 
<0.001* 
47.29 44.12 1.246 (161), 
0.214 
Social 
Impact 
47.48 43.64 2.09 (166), 
0.038 
49.13 40.92 5.91 (134), 
<0.001* 
46.99 44.44 1.015 (165), 
0.311 
 Priapism Severe, renal impairment: Requiring renal 
replacement treatment 
History of Retinopathy with visual impairment 
 
No Yes t(df), p No Yes t(df), p No Yes t(df), p 
Pain 
Impact 
49.77 44.33 1.952 (66), 
0.055 
47.66 43.14 1.442 (157), 
0.151 
47.83 45.34 1.205 (157), 
0.230 
Stiffness 
Impact 
51.21 45.93 2.012 (69), 
0.048 
49.78 43.45 2.137 (165), 
0.034 
50.05 46.96 2.039 (76), 
0.045 
Sleep 
Impact 
52.04 49.58 1.182 (66), 
0.242 
50.19 47.40 1.088 (161), 
0.278 
50.22 49.24 0.634 (161), 
0.527 
Emotional 
Impact 
49.23 46.58 0.955 (68), 
0.343 
47.21 41.75 1.720 (162), 
0.087 
47.09 45.98 0.573 (162), 
0.567 
Social 
Impact 
49.48 45.40 1.416 (69), 
0.161 
46.99 40.84 1.964 (166), 
0.051 
47.01 45.09 1.017 (166), 
0.311 
*Significant result (p<.01) 
Table S1 (continued). ASCQ-Me Medical History Differences 
 Catheter diagnosis of pulmonary hypertension Recurrent ankle ulceration during past 2 years Elevated tricuspid regurgitation (TR) jet 
velocity  
No Yes t(df), p No Yes t(df), p No Yes t(df), p 
Pain 
Impact 
47.22 55.80 -1.69 (156), 
0.092 
47.60 44.78 1.000 (157), 
0.319 
47.41 44.40 0.871 (155), 
0.385 
Stiffness 
Impact 
49.49 48.84 0.150 (164), 
0.881 
49.86 43.95 2.229 (165), 
0.027 
49.40 47.13 1.280 (14), 
0.222 
Sleep 
Impact 
50.07 48.36 0.478 (161), 
0.633 
49.96 50.61 -0.292 (161), 
0.770 
50.02 49.58 0.169 (159), 
0.866 
Emotional 
Impact 
47.10 42.90 0.909 (161), 
0.365 
46.93 45.89 0.362 (162), 
0.718 
47.00 42.64 1.313 (160), 
0.191 
Social 
Impact 
46.86  41.92 1.084 (165), 
0.280 
46.78 44.55 0.786 (166), 
0.433 
46.39 48.80 -0.726 (164), 
0.469 
*Significant result (p<.01) 
Table S2. Current treatment. Descriptive statistics for treatments taken by two or 
more participants. 
Treatment Number of participants currently taking 
treatment 
Antibiotic 137 
Folic acid 129 
Strong opioid 84 
Moderate strength opioid 82 
Paracetamol 57 
Non-steroidal anti-inflammatory 46 
Hydroxycarbamide 29 
Vitamin D 28 
Lansoprazole 11 
Iron chelation 10 
Amlodipine 7 
Anticoagulation 6 
Cyclizine 6 
Omeprazole 6 
Amitriptyline 5 
Aspirin 5 
Ramipril 5 
Senna 5 
Hydroxycholoroquine 4 
Calcium 3 
Citalopram 3 
Docusate sodium 3 
Gabapentin 3 
Phenoxymethylpenicillin 3 
Prednisolone 3 
Salbatamol 3 
Alendronic acid 2 
Azathiprine 2 
Ceterizine tablets 2 
Chlorophenamine 2 
Etilefrine 2 
Methotrexate 2 
Perindopril 2 
Pregablin 2 
Propranolol 2 
Seretide inhaler 2 
Solpadol 2 
Spironolactone 2 
Sulfasalazine 2 
 
